Is Fenofibrate a Reasonable Treatment for Diabetic Microvascular Disease?

Rafael Simó, Olga Simó-Servat, Cristina Hernández

Producció científica: Contribució a revistaArticle de revisióRecercaAvaluat per experts

14 Cites (Scopus)

Resum

© 2015, Springer Science+Business Media New York. Type 2 diabetes is a pandemic disease, and its prevalence is increasing mainly due to an increase in obesity and life expectancy. Diabetic complications and their comorbidities constitute the most important economic cost of the disease and represent a significant economic burden for the healthcare systems of developed countries. Despite improving standards of care, people with diabetes remain at risk of the development and progression of microvascular diabetic complications. Therefore, the identification of novel therapeutic approaches is necessary. The aim of this article is to provide an overview of the clinical benefits of fenofibrate on microvascular diabetic complications, with special emphasis on diabetic retinopathy. In addition, the potential mechanisms of action will be briefly discussed.
Idioma originalAnglès
RevistaCurrent Diabetes Reports
Volum15
Número5
DOIs
Estat de la publicacióPublicada - 1 de gen. 2015

Fingerprint

Navegar pels temes de recerca de 'Is Fenofibrate a Reasonable Treatment for Diabetic Microvascular Disease?'. Junts formen un fingerprint únic.

Com citar-ho